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 Abstract 
  Background:  Serum N-terminal pro-brain natriuretic peptide (NT-proBNP) is regarded as a sen-
sitive marker of cardiovascular disease. Vascular disease plays an important role in cognitive 
impairment.  Method:  In 447 elderly patients with mental illness, serum NT-proBNP level and the 
presence or absence of vascular disease according to the medical record were used to catego-
rize patients in different subgroups of vascular disease.   Results and Conclusion:   Patients  with 
vascular disease and elevated serum NT-proBNP level had a lower cognition level, shorter sur-
vival time, lower renal function and a higher percentage of pathological brain imaging than 
patients with vascular disease and normal NT-proBNP level. Thus, elevated serum NT-proBNP 
level might be helpful to detect patients who have a more severe cardiovascular disease. 
  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
  With an ageing population, the prevalence of dementia will continue to rise in the com-
ing decades, placing a high burden on social and economic resources. Since effective treat-
ments are lacking, prevention of dementia deserves high priority   [1, 2]  . In recent years, a re-
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lationship has been found between vascular disease and cognitive impairment in elderly 
patients with mental illness  [2] . Therefore, it is important to identify modifiable vascular risk 
factors, which could be used in preventing or delaying the onset of dementia   [2]  . Evidence 
has emerged that proper control of vascular disorders and maintenance of active lifestyle 
may prevent or delay the onset and progression of dementia   [2, 3]  .
    N-terminal pro-brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide 
(BNP) have an established role in identifying patients with heart failure, but these markers 
are also increased in myocardial ischaemia/coronary artery disease   [4–6]  . In previous stud-
ies in elderly patients with mental illness   [7, 8]  , we observed an increased frequency of path-
ological values of serum NT-proBNP in patients with vascular disease compared to patients 
without vascular disease. We concluded that the serum NT-proBNP level might be useful to 
identify patients in need of control and treatment of vascular risk factors and also provided 
prognostic information.
    Since many clinical and epidemiological studies published during the last 3 decades 
show that even mild hyperhomocysteinaemia is associated with vascular disease   [9–12]  , we 
investigated elderly patients with mental disease with regard to plasma homocysteine (tHcy) 
and the presence of vascular disease   [13–15]  . Briefly, our findings showed that patients with 
mental illness and any forms of vascular disease had significantly higher plasma tHcy con-
centrations than patients without vascular disease, and that elevated plasma tHcy in mental 
illness was mainly associated with the presence of vascular disease and not related to the 
specific psychogeriatric diagnosis.
    In the present study, we investigated NT-proBNP levels in different forms of vascular 
disease in elderly patients with mental illness. Furthermore, since serum NT-proBNP lev-
el has been associated with an increased risk of both cardiac   [4–6]   and noncardiac   [16] 
vascular diseases and might detect subclinical vascular disease, we have used serum NT-
proBNP level and the presence or absence of vascular disease according to the medical
records to categorize patients in four groups. Group I consisted of patients with vascular 
disease and an elevated level of serum NT-proBNP, whereas patients in Group II also 
showed the presence of vascular disease but with a normal level of serum NT-proBNP. Pa-
tients in Group III had no clinically overt vascular disease but an elevated level of serum 
NT-proBNP, and patients in Group IV showed no vascular disease and had a normal level 
of serum NT-proBNP. In order to study the possible use of serum NT-proBNP to evaluate 
vascular disease in elderly patients with mental illness, we investigated the distribution of 
different diagnoses, survival time, cognition (Mini-Mental State Examination, MMSE, 
score), brain imaging (computed tomography, CT, scan), renal function, and plasma tHcy 
in these four groups.
  Patients  and  Methods 
 Study  Population 
 The present study population consisted of 447 patients consecutively enrolled [187 males 
and 265 females, with a median age of 75 years (10–90th percentiles, 55–87)] who were re-
ferred to the Psychogeriatric Department at the Lund University Hospital for diagnostic as-
sessments and treatment. Patients on any kind of ongoing vitamin substitution were exclud-
ed from the study. The diagnosis was based on psychiatric, neurological, somatic, and labo-
ratory investigations, psychometric testing, measurements of regional cerebral blood flow, 
electroencephalography, and CT scan   [13]  . MMSE was performed in all patients   [17]  . The 
patients were classified into two groups on the basis of brain imaging findings: one group 
with normal findings (n = 217) and a second group with pathological findings (n = 177), 12
Dement Geriatr Cogn Disord Extra 2012;2:10–18
DOI: 10.1159/000334997
EXTRA
  Nilsson et al.: NT-proBNP in Elderly Patients with Mental Illness 
www.karger.com/dee
    © 2012 S. Karger AG, Basel
  Published online: February 3, 2012   
showing white matter lesions and/or cerebral infarction. The majority of the patients were 
living in their own homes, alone or with relatives. Dementia was diagnosed in 211 patients, 
77 patients were diagnosed with Alzheimer’s disease (AD), 89 patients with vascular demen-
tia (VaD), and 45 patients with other types of dementia (mainly mixed VaD and AD). In to-
tal, 236 patients were diagnosed with mental diseases without dementia (non-dementia), 51 
patients with depression, 6 patients with confusional states, 24 patients with other psychiat-
ric disorders (mainly psychosis), and 122 patients with mild cognitive impairment (MCI) 
  [18]  . In addition, 33 patients presented with subjective symptoms of cognitive impairment 
but normal psychometric tests. They had normal CT and were apparently healthy in other 
respects. These patients were treated as a separate group of patients called subjective cogni-
tive impairment. The diagnosis of the psychogeriatric diseases was based on the DSM-IV 
criteria   [19]  . Furthermore, patients with VaD fulfilled the NINDS-AIREN criteria   [20]   for 
VaD, and patients with AD were diagnosed in accordance with the NINCDS-ADRDA crite-
ria   [21]  . Survival time was determined as months at the end of the study (6 years) or months 
until death. The study was approved by the ethics committee of the University of Lund. In-
formed consent to participate was given by all subjects (or by relatives, if the patients were 
unable to communicate).
    The patients (n = 447) were divided into different groups according to the presence of 
a diagnosis and/or symptoms indicating vascular disease in their medical records. One 
group (n = 277) consisted of patients with any form of vascular disease and included diag-
noses/symptoms such as VaD, cerebral infarction, transient ischaemic attacks, myocardial 
infarction, angina pectoris, peripheral vascular disease, atrial fibrillation, and hyperten-
sion. A subgroup of these patients (n = 104) consisted of patients with manifest occlusive 
arteriosclerotic vascular disease (called manifest vascular disease) and included diagnoses/
symptoms such as cerebral infarction, transient ischaemic attacks, myocardial infarction, 
angina pectoris, or occlusive peripheral vascular disease. In 99 patients, hypertension was 
observed as the vascular disease. Cerebral infarction or transient ischaemic attacks were 
observed in 64 patients, myocardial infarction or angina pectoris in 40 patients,    atrial  fi-
brillation was diagnosed in 37 patients, and heart failure without any other vascular dis-
ease was diagnosed in 12 patients. In 170 patients, there was no indication of any vascular 
disease.
  A n a l y s e s  
  Blood samples for tHcy determination were collected in evacuated tubes containing 
EDTA at about 8 a.m. after an overnight fast and centrifuged within 15 min at 3,000   g   for
5 min. The plasma was stored at –20    °   C until analysis. Total plasma tHcy was measured with 
high-performance liquid chromatography after reduction of disulphide bonds with dithio-
threitol and deproteinization with sulphosalicylic acid   [22]  .
    Serum cystatin C measurements were performed by a polystyrene-enhanced turbidi-
metric method (DakoCytomation, Copenhagen, Denmark). The upper reference limits for 
serum cystatin C are 1.15 mg/l for subjects below 50 years of age and 1.44 mg/l for subjects 
above 50 years of age.
    The serum level of NT-proBNP was determined using an immunoassay (Modular Ana-
lytics E170; Roche Diagnostics, Mannheim, Germany). The upper reference limit is 300 ng/l.
  S t a t i s t i c s  
  The results are presented as medians and 10–90th percentiles. The Mann-Whitney U 
test was used at the 5% level of significance to evaluate the study. The     2   test was used for 
comparison of percentages of pathological CT findings.13
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  R e s u l t s  
  Different Forms of Vascular Disease 
 Levels of serum NT-proBNP, plasma tHcy, and serum cystatin C were elevated in all groups 
of patients with different forms of vascular disease compared to patients without vascular dis-
ease ( table 1 ). Furthermore, correction for the age difference between patients with and without 
vascular disease did not change the significant elevations of serum NT-proBNP, plasma tHcy, 
and serum cystatin C (data not shown). Notably, the levels of serum NT-proBNP were particu-
larly increased in patients with atrial fibrillation. Patients with hypertension exhibited similar 
serum NT-proBNP level than the other groups of patients with vascular disease.
    Patients without vascular disease according to their medical records but with an elevat-
ed level of NT-proBNP showed elevated levels of plasma tHcy and serum cystatin C com-
pared to patients with vascular disease but a normal level of serum NT-proBNP (  table 2 ).
    Subgroups of Vascular Disease 
  All patients were divided into four groups depending on their level of NT-proBNP and 
the presence or absence of vascular disease according to their medical records (  table 3 ). 
Table 1.   Age, serum NT-proBNP, plasma tHcy, and serum cystatin C in different groups of patients with and without vas-
cular disease
n Age
years
Serum NT-proBNP
ng/l
Plasma tHcy
mol/l
Serum cystatin C
mg/l
No vascular disease 170 68 (48–82) 115 (27–368) 11.6 (7.7–19) 0.85 (0.65–1.12)
Vascular disease 277 78 (62–88)** 298 (67–2,333)*** 15.1 (9.3–23.6)*** 1.04 (0.74–1.44)***
No MVD 150 77 (61–88)*** 324 (61–2,318)*** 14.7 (9.1–23)*** 1.06 (0.73–1.55)***
MVD 104 80 (66–88)*** 290 (86–2,500)*** 15.3 (9.6–23.6)*** 1.04 (0.76–1.41)***
CI or TIA 64 79 (69–88)*** 273 (75–1,731)*** 15.6 (10–23.3)*** 1.02 (0.79–1.39)***
Atrial fibrillation 37 81 (66–90)*** 1,004 (109–2,985)*** 17.6 (11.1–28.0)*** 1.14 (0.79–1.84)***
Hypertension 99 75 (60–89)*** 250  (56–1,299)*** 13.7 (8.7–23)* 0.99 (0.7–1.34)**
MI or angina 40 80 (57–88)*** 331  (102–6,074)*** 14.9 (8.8–26.9)** 1.08 (0.72–1.41)**
Heart failure 12 74 (58–85) 311 (79–2,942)** 14.2 (10.3–20.9)* 1.02 (0.83–1.63)*
V  alues represent medians (10–90th percentiles). MVD = Manifest occlusive vascular arteriosclerotic disease; CI = cer-
ebral infarction; TIA = transitory ischaemic attack; MI = myocardial infarction; angina = angina pectoris.
* p < 0.05; ** p < 0.01; *** p < 0.001. Patients with different forms of vascular disease are compared to patients without 
vascular disease.
Table 2.   Age, serum NT-proBNP, plasma tHcy, and serum cystatin C in patients without vascular disease but elevated NT-
proBNP level and in patients with vascular disease but normal level of serum NT-proBNP
n Age
years
Serum NT-proBNP
ng/l
Plasma tHcy
mol/l
Serum cystatin C
mg/l
No VD but elevated NT-proBNP 23 78 (68–90) 549 (305–2,400) 14.5 (10.6–30.8) 1.1 (0.83–1.4)
VD but normal NT-proBNP 140 74 (58–84)** 135 (44–271)*** 13.1 (8.8–20)* 0.92 (0.72–1.3)**
V  alues represent medians (10–90th percentiles). VD = Vascular disease.
* p < 0.05; ** p < 0.01; *** p < 0.001. Patients without vascular disease but elevated NT-proBNP are compared to patients 
with vascular disease but normal level of serum NT-proBNP.14
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Group I consisted of patients with vascular disease and an elevated level of serum NT-
proBNP, whereas patients in Group II also showed the presence of vascular disease but with 
a normal level of serum NT-proBNP. Patients in Group III had no clinically overt vascular 
disease but an elevated level of serum NT-proBNP, and patients in Group IV showed no vas-
cular disease and had a normal level of serum NT-proBNP. In Groups I–III, the levels of se-
rum NT-proBNP, plasma tHcy, and serum cystatin C were elevated, and the survival time 
was lower than in Group IV. The MMSE score was lower and the frequencies of pathological 
CT findings were higher in Groups I and II than in Group IV.
    The patients in Group I were older and showed increased plasma tHcy and serum cys-
tatin C levels, lower MMSE score, shorter survival time, and an increased percentage of 
pathological CT findings compared to the patients in Group II.
    Distribution of Diagnoses in the Subgroups 
 The distribution of the main diagnoses (VaD, AD, MCI, and depression) in the four sub-
groups is presented in   table 4  . Patients with VaD were observed only in Groups I and II. Pa-
tients with AD were substantially observed in all groups, whereas only a few patients with 
MCI (n = 3) and depression (n = 2) were observed in Group III. Patients with VaD and an 
Table 3.   Age, serum NT-proBNP, plasma tHcy, serum cystatin C, MMSE score, and survival time in patients with different 
vascular diseases
n Age
years
Serum NT-
proBNP, ng/l
Plasma tHcy
mol/l
Serum cystatin C
mg/l
MMSE score Survival time
months
Pathologi-
cal CT, %
Group I 137 81 (71–90)***, a 841 (346–3,914)***, a 16.0 (11.1–26.4)***, a 1.1 (0.83–1.58)***, a 21 (13–27)***, a 38 (6–56)***, a 71***, b
Group II 140 74 (58–84)*** 135 (44–271)*** 13.1 (8.8–20)** 0.92 (0.72–1.3)*** 26 (17–29)** 46 (17–61)* 60***
Group III 23 76 (68–90)*** 549 (304–2,400)*** 14.5 (10.6–30.8)*** 1.1 (0.82–1.4)*** 26 (16–29) 37 (4–53)*** 35
Group IV 147 65 (47–80) 98 (23–225) 11.0 (7.6–18.2) 0.83 (0.65–1.03) 27 (20–30) 49 (31–62) 28
V  alues represent medians (10–90th percentiles).
* p < 0.05; ** p < 0.01; *** p < 0.001. Patients in Groups I–III are compared to patients in Group IV. 
a p < 0.001; b p < 0.05. Patients in Group I are compared to patients in Group II.
Table 4.   The main diagnoses (VaD, AD, MCI, and depression) subdivided according to different forms (Groups I–IV) of 
vascular diseases
n Age
years
Serum NT-proBNP
ng/l
Plasma tHcy
mol/l
Serum cystatin C
mg/l
MMSE score Survival time
months
Pathologi-
cal CT, %
VaD, Group I 58 83 (73–91) 882 (371–3,889) 16.4 (10.7–309) 1.12 (0.81–1.56) 19 (11–25) 25 (4–54) 90
VaD, Group II 31 80 (68–86)* 144 (57–285)*** 16.0 (9.3–29.6) 1.0 (0.79–1.49) 21 (11–28) 36 (12–59)* 90
AD, Group I 17 81 (76–92)** 601 (305–7,929)*** 16.9 (11.7–23.6) 1.12 (0.92–1.64)*** 18 (11–25) 37 (5–61) 41
AD, Group II 16 77 (68–86) 178 (75–272) 14.0 (7.9–22.8) 0.96 (0.74–1.38) 21 (10–29) 40 (7–62) 44
AD, Group III 11 81 (69–94) 493 (303–2,125)*** 15.5 (10.4–42) 1.07 (0.8–1.48)* 26 (15–29) 33 (1–58) 18
AD, Group IV 33 77 (63–85) 136 (48–245) 15.0 (9.3–19.4 0.91 (0.68–1.07) 22 (11–27) 41 (29–59) 18
MCI, Group I 26 78 (62–88)*** 633 (318–4,394)*** 16.0 (10–23.2)*** 1.13 (0.73–1.59)*** 26 (19–29)** 44 (13–58)* 54**
MCI, Group II 45 68 (57–79)** 122 (39–276)* 12.9 (9.3–16.6)** 0.86 (0.69–1.18)** 27 (21–30) 50 (35–61) 56***
MCI, Group IV 48 61 (47–77) 85 (23–179) 10.1 (7–15.9) 0.74 (0.62–0.92) 28 (24–30) 52 (32–64 25
Depression, Group I 9 81 (72–90)*** 609 (321–13,978)*** 17.9 (9.7–36.2)** 1.08 (0.66–2.65)** 26  (17–29)* 39 (9–62) 56
Depression, Group II 15 63 (55–86) 109 (27–264) 10.7 (8.3–17.3) 0.89 (0.71–1.56 29 (24–30) 41 (19–59) 40
Depression, Group IV 25 65 (47–78) 89 (11–272) 10.1 (7.1–16.6) 0.85 (0.64–1.09) 29 (22–30) 42 (23–54) 32
V  alues represent medians (10–90th percentiles).
* p < 0.05; ** p < 0.01; *** p < 0.001. Patients in Groups I–III are compared to patients in Group IV.15
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elevated level of serum NT-proBNP (Group I) were older (p   !   0.001) and showed a shorter 
survival time (p   !   0.001) than patients with a normal level of serum NT-proBNP (Group II).
    Patients with AD in Group I were older and showed an increased serum cystatin C level 
(plasma tHcy was almost significantly increased, p = 0.07) compared to those in Group IV, 
whereas patients in Group II did not differ in any parameter from patients in Group IV. Pa-
tients with AD and an elevated serum NT-proBNP (Groups I and III) were older and showed 
increased levels of plasma tHcy and serum cystatin C as well as an increased percentage of 
pathological CT findings compared to patients with a normal level of serum NT-proBNP 
(Groups II and IV) (  table 5 ).
  Patients with MCI in Group I were older and showed increased levels of plasma tHcy and 
serum cystatin C, decreased MMSE score, shorter survival time, and an increased percent-
age of pathological CT findings compared to patients in Group IV (  table 4  ). Likewise, pa-
tients with MCI in Group II were older and showed increased levels of plasma tHcy and se-
rum cystatin C and an increased percentage of pathological CT findings compared to pa-
tients in Group IV. Patients with depression in Group I were older and showed increased 
levels of plasma tHcy and serum cystatin C and a decreased MMSE score compared to pa-
tients in Group IV, whereas patients with depression in Group II did not differ in any param-
eter from patients in Group IV.
  Discussion 
  Different Forms of Vascular Disease 
  The present study shows that patients with different forms of vascular disease exhibited 
an elevated level of NT-proBNP compared to patients without vascular disease. Thus, these 
findings are in agreement with previous reports suggesting that the presence of cardiovas-
cular disease increases the level of serum NT-proBNP   [4–6, 16]  . About half of the patients 
classified as having vascular disease according to their medical records showed normal lev-
els of serum NT-proBNP. A possible reason for this discrepancy is that their vascular disease 
did not significantly involve the heart. The elevated levels of serum NT-proBNP in 23 pa-
tients diagnosed as having no vascular disease according to their medical records might be 
attributed to renal impairment and/or subclinical cardiovascular disease.
    The increase of serum NT-proBNP levels in most of the different forms of vascular dis-
ease suggests similar cardiac involvement irrespective of whether the vascular disease is of 
cerebral or extracerebral origin, occlusive or not occlusive, or only manifests itself as hyper-
tension. Thus, this finding indicates a generalized vascular disease also in patients diagnosed 
with cerebral vascular disease. The level of serum NT-proBNP was, however, particularly in-
creased in patients with atrial fibrillations, which is in agreement with a highly elevated serum 
NT-proBNP level in atrial distention   [4–6]  . As previously shown   [23]  , plasma tHcy was also 
elevated to a similar extent in the different forms of vascular disease compared to patients 
Table 5.   Patients with AD with normal and elevated serum NT-proBNP
n Age 
years
Serum NT-proBNP
ng/l
Plasma tHcy
mol/l
Serum cystatin C
mg/l
MMSE score Survival time
months
Pathologi-
cal CT, %
Elevated NT-proBNP 28 81 (73–91)*** 528 (304–3,185)*** 16.3 (11.1–29.6)* 1.08 (0.81–1.55)*** 20 (12–27) 37 (3–59) 32*
Normal NT-proBNP 49 77 (64–84) 145 (61–250) 14.8 (9–19.6) 0.92 (0.74–1.17) 22 (12–27) 41 (12–61) 26
V  alues represent medians (10–90th percentiles).
* p < 0.05; *** p < 0.001. Patients with elevated serum NT-proBNP are compared to patients with normal serum NT-proBNP.16
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without vascular disease. Likewise, the level of serum cystatin C was increased to a similar 
extent in the different forms of vascular disease, which indicates similar renal impairment in 
all these vascular diseases. Furthermore, in patients without vascular disease but with an
elevated level of serum NT-proBNP, the levels of plasma tHcy and serum cystatin C were in-
creased compared to patients with vascular disease but a normal level of serum NT-proBNP. 
This finding indicates that the serum NT-proBNP level might be a better indicator of the se-
verity of the vascular disease than solely the diagnosis and/or presence of symptoms of vas-
cular disease.
    Renal Function and Vascular Disease 
  Renal impairment is known to increase the serum level of NT-proBNP   [4–6]  , and it is 
therefore expected that patients with an elevated level of serum NT-proBNP also show a low-
ered renal function (as judged by serum cystatin C) compared to patients with a normal level 
of NT-proBNP. Cystatin C is a sensitive marker of renal impairment, and chronic renal dis-
ease is known to be an important cardiovascular risk factor   [24, 25]  . This fact is in agreement 
with our findings from previous studies   [7, 8]   and from the present study, where we observed 
that serum cystatin C is associated with serum NT-proBNP and plasma tHcy levels, the pres-
ence of vascular disease, and pathological CT findings (indicating cerebrovascular disease).
    Subgroups of Vascular Disease 
  As described in the Results section, all patients were divided into four groups according 
to their level of serum NT-proBNP and the presence or absence of vascular disease as indi-
cated in the medical records. Patients in Group I could be regarded as having a more severe 
form of vascular disease than those in Group II, which was supported by the findings that 
patients in Group II were younger, showed lower plasma tHcy and serum cystatin C levels, 
higher MMSE score, a lower percentage of pathological CT findings, and a longer survival 
time than patients in Group I. All patients in Groups I–III could be regarded as patients with 
vascular disease, even if the cardiovascular disease in Group III was only manifested as an 
elevated level of serum NT-proBNP. Patients in Group IV represent a group of patients with-
out any signs of vascular disease. Consequently, patients in Groups I–III showed higher 
plasma tHcy and serum cystatin C levels and a shorter survival time, and patients in Groups 
I and II also showed a lower MMSE score and higher percentage of pathological CT findings 
than patients in Group IV. These findings indicate that the presence or absence of vascular 
disease according to the medical records means that some patients with cardiovascular dis-
orders are classified as having no vascular disease despite an elevation of their serum NT-
proBNP levels.
    Distribution of Diagnoses in the Four Subgroups 
  The distribution of the main diagnoses (VaD, AD, MCI, and depression) in the different 
groups of vascular disease shows that patients with VaD in Group I exhibited a somewhat 
higher age and a shorter survival time than patients in Group II. Furthermore, an elevated 
level of serum NT-proBNP in patients with VaD in Group I indicates that these patients also 
suffer from cardiovascular disease in addition to their cerebral vascular disease. The shorter 
survival time in these patients might thus be attributed to a more generalized vascular disease.
    Subgrouping of the other main diagnoses (AD, MCI, and depression) in these four sub-
groups showed that plasma tHcy, renal function (as judged by serum cystatin C), MMSE 
score, survival time, and percentage of pathological CT findings differed between the groups. 
These findings indicate that the determination of serum NT-proBNP might be useful in the 
evaluation of vascular disease in elderly patients with mental illness. Few patients with MCI 
or depression were observed in Group III, which indicates a significant agreement between 17
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serum NT-proBNP level and the presence or absence of vascular disease according to medi-
cal records. However, patients with AD were substantially represented in all four groups, and 
serum cystatin C was elevated in Groups I and III compared to Group IV, whereas plasma 
tHcy showed a tendency to increase (p = 0.07) only in Group I. It is particularly interesting 
that a substantial proportion of the patients with AD (Group III) without vascular disease 
had an elevated level of serum NT-proBNP, indicating subclinical cardiovascular disease. 
Patients with AD in Groups I and III might have a more severe form of vascular disease than 
the patients in Group II, which is reflected by the fact that, although there was no significant 
decrease in the MMSE score and survival time, patients with AD and elevated serum NT-
proBNP level (Groups I and III) were older, showed lower renal function, an increased plas-
ma tHcy level, and a higher percentage of pathological CT findings compared to patients 
with AD and a normal level of serum NT-proBNP (Groups II and IV). This finding supports 
the hypothesis that neurovascular interactions in the development and/or progression of AD 
have been underappreciated   [26]  . Therefore, it is important to determine the serum NT-
proBNP level in patients with AD to detect those in need of treatment of their vascular dis-
ease in order to prevent or delay cognitive impairment.
  Conclusion 
  The main finding in the present study is that serum NT-proBNP levels are similarly in-
creased in most of the different forms of vascular disease, which suggests similar cardiac 
involvement irrespective of whether the vascular disease is of cerebral or extracerebral ori-
gin, occlusive or not occlusive, or only manifests itself as hypertension. Furthermore, pa-
tients with vascular disease and an elevated serum NT-proBNP level (Group I) had a lower 
cognition level, shorter survival time, lower renal function, and a higher percentage of path-
ological CT findings than patients with vascular disease and a normal NT-proBNP level 
(Group II). Thus, an elevated serum NT-proBNP level might detect patients who have a more 
severe cardiovascular disease and therefore a higher risk of rapid progression of their vascu-
lar disease and mental illness. These patients are in need of more intensive control and treat-
ment of their vascular disease to prevent or delay cognitive impairment.
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